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Advancing the Understanding of Pharmaceutical Supply Chain Resilience
using Complex Adaptive System (CAS) Theory




The objective of this study was to advance our knowledge of pharmaceutical supply chain
resilience using Complex Adaptive System theory (CAS).
Design/methodology/approach
An exploratory research design which adopted a qualitative approach was used to achieve the
study’s research objective. Qualitative data were gathered through 23 semi-structured
interviews with key supply chain actors across the PSC in the United Kingdom (UK).
Findings
The findings demonstrate that CAS, as a theory, provides a systemic approach to
understanding PSC resilience by taking into consideration the various elements (environment,
PSC characteristics, vulnerabilities and resilience strategies) that make up the entire system.
It also provides explanations for key findings, like the impact of power, conflict and
complexity in the PSC, which are influenced by the interactions between supply chain actors
and as such increase its susceptibility to the negative impact of disruption. Furthermore, the
antecedents for building resilience strategies were the outcome of the decision-making
process referred to as co-evolution from a CAS perspective.
Originality/value
Based on the data collected, the study was able to reflect on the relationships, interactions and
interfaces between actors in the PSC using the CAS theory, which supports the proposition
that resilience strategies can be adopted by supply chain actors to enhance this service supply
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chain. This is a novel empirical study of resilience across multiple levels of the PSC and as
such adds valuable new knowledge about the phenomenon and the use of CAS theory as a
vehicle for exploration and knowledge construction in other supply chains.
Keywords: Pharmaceutical Supply Chain; Disruptions; Resilience Strategies; Vulnerabilities;
Complex Adaptive System Theory.
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1. Introduction
The COVID-19 pandemic, which has already led to deaths globally (World Health
Organisation, 2020), is the latest example of a disruptive event that highlights the need to
understand pharmaceutical supply chain resilience. There have been many other events which
have impacted on the pharmaceutical supply chain (PSC). For instance, the Food and Drug
Administration (FDA) announced shortage of twenty (20) medicines which had their sole
source of Active Pharmaceutical Ingredients (API) or finished medicines from China (Rees,
2020). Apart from shortages of medicinal products affecting the financial and operational
performance of firms within the supply chain (SC), they also significantly increased the cost
of healthcare for patients and potentially led to the death of patients (Mereish et al., 2018;
Phuong et al., 2019). Disruptions in supplying pharmaceutical products, thus depict an
adverse impact on the whole health care system (Pauwels et al., 2015). For example, patients
requiring extra therapeutic care (McLaughlin, 2013), increased stress on the staff (De Weerdt
et al., 2017) and increased costs for the stakeholders (Fox et al., 2014). The increased
discussions about disruptions to the PSC calls for closer scrutiny of this service supply chain
as well as the need to seek ways in preventing and/or mitigating the impact of disruptive
events.
Existing studies suggest that underlying weaknesses (vulnerabilities) expose supply chains to
the impact of disruptions (Wagner and Bode, 2006; Craighead et al., 2007). Nonetheless, by
building resilience strategies into supply chains, vulnerabilities may be reduced, and the
capacity of supply chains to mitigate the impact of disruptive events increased (Christopher
and Peck, 2004; Juttner and Maklan, 2011; Li et al., 2020). SC resilience thus involves the
ability of the supply chain to prepare, respond and recover from a disruptive event in a timely
and cost-effective manner (Tukamuhabwa et al., 2015; Hendry et al., 2019).
Although there have been extensive discussions in the literature around SC resilience (Chopra
and Sodhi, 2014; Hendry et al., 2019), specific focus on resilience strategies in the PSC
remains limited. The need for studies in PSC resilience is because the impact of disruptions
transcends beyond losses in revenue and market shares to involve decisions regarding
patients' safety. Thus, strategies adopted may differ from other supply networks (Jaberidoost
et al., 2013; Lucker and Seifert, 2017).
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Also, it is suspected that; the PSC differs from other supply chains. Some of the
characteristics include longer lead times, stringent regulatory frameworks, difficult demand
forecasting and complex applications which may influence the applicability of resilience
strategies (Rossetti et al., 2011; Klueber and O'Keefer, 2013; Mehralian et al., 2015).
However, these conclusions may stem from limited scope in the current understanding of
PSC resilience as the studies have not approached it from a systemic perspective. Thus, once
PSC resilience is viewed as a Complex Adaptive System (CAS) that is non-linear and
exhibits various internal and external elements, it would become apparent that it should be
approached from a systemic perspective.
CAS theory is defined as the dynamic ability of systems to adapt and evolve to changes in an
environment (Choi, 2001; Day, 2014; Nair and Reed-Tsochas, 2019). We apply the
components of CAS theory (internal, external and co-evolution) in this study, to examine as
well as enhance our understanding of the complex dynamics of resilience in PSC as a service
supply chain. We posit that PSC resilience is a CAS and provide empirical evidence to
affirm our propositions. In adopting this position, we argue that advancing the knowledge of
PSC resilience through a CAS lens permits us to gain maximum insight into practical
approaches for building resilience into the PSC.
This study, therefore, seeks to advance our knowledge of PSC resilience using Complex
Adaptive System theory. We begin by reviewing supply chain literature to report underlying
assumptions about PSC, disruptions, vulnerabilities, resilience strategies and CAS. Through
this, gaps in the literature are highlighted and inform the research objective as well as the
methodological approach used. We then present the findings from interviews conducted with
a purposive sample of selected supply chain actors before establishing connections between
PSC resilience and CAS theory. The study concludes by underlining the novel contribution of
this work, proposals for further study and recommendations for practice. At this point, we
also offer considerations for the generalisability of the approach and outputs of this study to
other complex supply chains.
2. Literature Review
A review of the extant literature is presented here. In Section 2.1 below, CAS theory is
briefly described. Section 2.2 presents the importance of the PSC and supply chain
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disruptions. Sections 2.3 and 2.4 reviews the concepts of supply chain vulnerabilities and
resilience strategies respectively as well as the gaps in the literature that need to be addressed.
2.1 Complex Adaptive System (CAS) Theory
Several theories have been employed to elucidate resilience as a phenomenon within the
supply chain literature: Resource-Based View (RBV) (Holweg and Pil, 2008; Blackhurst et
al., 2011); Dynamic Capability Theory (Ponomarov, 2012; Hendry et al., 2019) and Systems
Theory (Erol et al., 2010; Spiegler et al., 2012). Table 1 below presents a summary of the
theories and discusses their limitations for gaining an understanding of PSC resilience
(PSCR).
Table 1 Summary of theories used in supply chain resilience literature
Theories Use in SC resilience studies Limitations for PSCR
discussions
Resource Based View (RBV)
Holweg and Pil (2008);
Ponomarov and Holcomb, (2009);
Park (2011); Bradon-Jones et al.,
(2014); Brusset and Teller, 2017;
Cheng et al., (2017) Dubey et al.,
(2017); Parast (2020).
SC resilience is the firm’s
redundant, capital or flexible
resources which is used to
gain competitive advantages.
Resilience strategies are
limited to a firm’s internal
environment and within a
complex supply chain.
Dynamic Capability Theory:
Chowdhury and Quaddus, (2017);
Gu and Huo (2017); Hendry et al.,
(2019); Sabahi and Parast, (2019).
SC resilience is the ability of
the firm to sense and adapt to
changes in the external
environment that will foster
sustainability and
competitiveness.
The theory does not explain
the systemic nature of SC
resilience.
System Theory:
Erol et al., (2010); Blackhurst et
al.,(2011); Spiegler et al., (2012);
Kaviani et al., (2016)
The SC is viewed as an open
system that constantly
interacts with its environment
and resilience strategies are
elements within the supply
chain.
The theory does not explain
the dynamism and
adaptability in SC resilience.
In line with the studies by Day (2014) and Tukamuhabwa et al., (2015), we, therefore, assert
that PSC resilience strategies cannot be viewed as just a system or resources as they are more
complex in nature. The argument stems from the dynamism of the external environment, the
multidimensionality of resilience strategies and the uncertainties associated with the inherent
complexity of the PSC. This study proposes the Complex Adaptive System (CAS) theory to
advance our knowledge on PSC resilience as it deals with high levels of abstractions
6
concerning business environments. (Choi et al., 2001; Holland, 2006). Some authors (Sarkis
et al., 2011; and Kim et al., 2015), suggest the need to understand how firms in such complex
networks coevolve with one another to determine appropriate responses to external stimuli.
This will help businesses to gain competitive advantages from their complex interactions with
their environment.
A CAS comprises of a range of elements, referred to as agents who follow sets of internal
rules or schemas that guide their actions (Choi et al., 2001). These schemas provide the
agents with reference points for their behaviour. They can be applied to new situations rather
than assessing new rules for every possible situation (Nair and Reed-Tsochas, 2019).
The theory emerged to provide explanations as to how order exists within systems that are
complex and non-linear, such as the human system and the galaxy (Holland, 2006). A CAS
focuses on the interactions between the agents and their changing environment. In its ability
to learn from its experience, a CAS evolves based not only on the dynamic interactions
amongst its agents but also on the interactions between the environment and the agents
(Schiffling et al. 2020). New behaviours emerge based on the interactions between each agent
and the overall system. Agents can be eliminated, or new agents emerge because of
interactions. Since most of the interactions between agents and their environment are non-
linear, the outcome and/or the behaviour of the system is usually unpredictable (Choi et al.,
2001). A CAS is deemed complex and adaptive because it is diverse, can alter itself based on
learning from experience (Holland, 2006); and possesses the ability to anticipate the
consequences of new actions or activities. CAS theory has gained popularity in the social
sciences, for example in stock markets (Mauboussin, 2002); healthcare management (Pype et
al., 2019; Fylan et al., 2019) and supply chain networks (Choi et al. 2001; Surana et al., 2005;
Day, 2014; Nair et al., 2016; Schiffling et al. 2020).
Choi et al., (2001) and recently updated by Nair and Reed-Tsochas (2019), provide a CAS
framework as presented in Table 2. This framework categorises elements of CAS into three
significant dimensions which are the internal mechanisms, the external mechanisms and co-
evolution. It is against this categorisation that the contribution of CAS theory to
pharmaceutical supply chain resilience will be drawn.
Table 2 CAS Framework
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Elements of CAS Features Inference
Internal Agents, schemas, network,
connectivity, dimensionality, non-
linearity. Agents are organisations
supply chain actors
Concerned with how agents
interact with each other within a
system.




Concerned with the external
environment in which the system
operates and how agents respond
to changes in the environment
Coevolution Adaptability, anticipation, self-
organisation, emergent behaviour.
Characterises the ability of the
system to be flexible, respond
and react to changes because of
the interactions.
The complex interactions within the PSC, its non-linearity, unpredictable outcomes and the
dynamism associated with resilience strategies advocate CAS theory in for advancing our
understanding of PSC resilience. Thus, if the understanding of PSC resilience is
oversimplified, it may create issues that inhibit the success of the application of the
underlying strategies. The next section presents an overview of PSC disruptions and features
2.2 Disruptions within the Pharmaceutical Supply Chain (PSC)
The PSC consists of multifaceted procedures and operations that facilitate medicine
discovery, development, manufacture and distribution under highly regulated conditions
(Narayana et al., 2014). The aim is to ensure that the supply of medicines is safe, reliable and
meets the set quality criteria through a supply chain which responds to actual demand and
recognises the needs of the consumer (Sousa et al., 2015). See Figure 1 for an overview of the
PSC.
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Figure 1. The Pharmaceutical Supply Chain
Source: Adapted from Evans and Gruber (2014)
*LSP: - Logistic Service Provider
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Existing reports indicate an upsurge in global sales as a result of increased access to
healthcare in various countries and increased prices for breakthrough medicines (Singh et al.,
2016; Sabouhi et al., 2018). However, the increased incidences of disruptions-medicine
shortages- in the PSC (Beck et al., 2019), call for closer scrutiny of how resilience strategies
can be built to ensure the continuous flow of medicines and as such advance our
understanding of this service supply chain.
Disruptions are events that disrupt the flow of goods and services within an SC and have been
reported to have adverse effects on the financial and operational performance of the firm
(Hendricks et al., 2019). SC disruption does not differ significantly from supply chain risk;
instead, it is a realised risk (Habermann et al., 2015). Dynamic disruptions extend the concept
of supply chain disruptions to include disruptions where the mode of occurrence and impact
is largely unknown as with medicine shortages. It is therefore crucial to understand the
concept and classification of disruption within the SC as it relates to risks, vulnerability and
resilience to pre-empt a response and inform actual response (Juttner and Maklan, 2011).
Medicine shortages have been identified as a supply issue, yet there are limited studies that
address this issue from a SC perspective. For instance, Saedi et al. (2016) advocated the use
of optimisation techniques in curbing medicine shortages. In addition, Tucker et al. (2019)
used optimisation techniques to study the resilience of the PSC to medicine shortages in the
US. Their study concluded that deliberate managerial decisions were a primary vulnerability
driver within PSCs, but this was targeted at low-cost medicines. Jia and Zhao (2017)
presented the use of inventory management through Pareto improving contracts, while Scioli
(2017) suggested the use of leadership strategies in curbing medicine shortages. The findings
from these studies show the importance of exploring medicine shortages, vulnerabilities, PSC
resilience. Thus advancing our understanding is pertinent.
For this study, medicine shortages will be explored as the dynamic, disruptive activity that
affects the PSC, the underlying vulnerabilities and resilience strategies. The next section
discusses the relationship between SC vulnerability and PSC resilience.
2.3 Supply Chain Vulnerability (SCV)
Supply chain vulnerability is the susceptibility of the SC to the impact of disruption (Peck,
2005; Wagner and Bode, 2006; Chowdhury and Quaddus, 2017). Proponents of supply chain
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resilience suggest that resilience and vulnerabilities are interwoven, and not all disruptive
activities can be avoided, controlled, or eliminated (Juttner and Maklan, 2011). Pettit et al.,
(2010) validated this through an empirical study that found that supply chain resilience
increases as capabilities increases and vulnerabilities decrease. Similarly, Christopher and
Holweg (2017), provided quantitative evidence that SCV resulted in higher costs and
therefore resilience was advocated. Therefore, understanding SCV is pertinent to effectively
manage SCV (Wagner and Bode, 2006; Wagner and Neshat, 2012).
Although drivers of SCV have been highlighted in existing literature, empirical evidence is
limited. For instance, supply chain density and structure has been identified as a primary
propellant of SC vulnerability as tightly coupled suppliers inhibits flexibility of operations
(Wagner and Bode, 2006; Craighead et al., 2007; Falasca et al., 2008). Complexity as an
SCV driver occurs as a result of managerial decisions, globalisation and outsourcing has been
suggested to heighten the severity of a disruption as well as increase risks (Bode et al., 2016;
Blackhurst et al., 2017). These activities lead to more prolonged and multiple layered SCs
which reduce visibility and increase vulnerability, plant performance, production costs, and
supplier innovation (Wagner and Neshat 2010).
SC power denotes the ability of a SC actor to influence the outcomes of other actors at
different levels of the supply chain (Benton and Maloni, 2005; Golgeci et al., 2018). Power
dynamics have been identified as central to SC relationships (Reimann and Ketchen, 2017).
However, the possibility that power may increase vulnerabilities in the SC has not received
much attention in SC resilience literature. The argument is that power asymmetry; where one
firm needs another firm's resources (Huo et al. 2017) and therefore holds less power, may
expose the SC to the impact of disruptions. Thus, the more powerful firms have been
suggested to have higher market share and may use power to gain a competitive advantage.
Resilience strategies should be incorporated into the SC to reduce power dynamics and
mitigate the impact of disruptions.
2.4 Supply Chain Resilience
An approach to dealing with the impact of disruptive events in an SC is by adopting
resilience strategies (Juttner and Maklan, 2011; Melnyk, et al., 2014). This study adopts the
definition of SC resilience proposed by Tukamuhabwa et al., (2015:5599) as "The adaptive
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capability of a supply chain to prepare for and/or respond to disruptions, to make a timely
and cost-effective recovery, and therefore progress to a post-disruption state of operations –
ideally, a better state than prior to the disruption". This is because it encompasses the
essential ingredients of what a resilient SC entail.
SC resilience relates to balancing both recovery and resistance strategies (Melnyk et al., 2014;
Sáenz and Revilla, 2014; Christopher and Holweg, 2017; Chowdhury and Quaddus, 2017).
Recovery as an arm of resilience strategies implies that the SC adjusts ex-post to changes, and
SCs adopting this strategy are referred to as agile supply chains (Braunscheidel and Suresh,
2009). Resistance strategies, however, imply that the supply chain implements ex-ante
measures to cope with turbulence, with no adaptation needed during times of change. SC
adopting this strategy are robust supply chains (Klibi et al., 2010; Vlajic et al., 2012).
Relevant studies in this area have focused on critical aspects of SC resilience. For instance,
flexibility and collaboration (Juttner and Maklan, 2011); relational capabilities (Toyli et al.,
2013); resilience scale development (Ambulkar et al., 2015); collaboration with the
government (Yang and Xu, 2015); interface of resilience and sustainability (Ivanov, 2018);
building routine for non-routine events (Scholten et al., 2017); resilience strategy model
development (Jain et al., 2017); the interrelatedness of threats, resilience strategies and
outcomes arguing for a systemic approach to supply chain resilience (Tukamuhabwa et al.,
2017) and seizing and sensing capabilities required in building SC resilience (Hendry et al.,
2019). Although these studies have examined resilience strategies in parts, most have
identified the need for more empirical research since resilience strategies are dynamic and
cannot be restricted to specific parts of the SC. In order to advance our knowledge of
resilience strategies a holistic or systemic approach is needed .
2.5 The Relationship between CAS and Resilience in the PSC
In seeking to advance the discussions around PSC resilience, a clear rationale needs to be
identified. Issues reported which impact on SC resilience in the PSC include visibility,
vulnerability, product life cycle and system maturity as indicated by the studies presented in
Table 3.
Table 3 shows that previous studies failed to explain why vulnerabilities occurred in the
supply chain and how resilience strategies could be used in mitigating the vulnerabilities.
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Also, there was no practical use of theory in any of the studies, and these studies failed to
adopt a systemic approach to understanding how the various elements of PSC resilience
(vulnerabilities and antecedents of resilience strategies) are interrelated. This litersture review
provides conclusive evidence to support the need for a holistic approach. This study,
therefore, posits that if PSC resilience is explored from a CAS perspective, which adopts a
holistic approach, our understanding of PSC resilience will be enhanced.
Table 3 Empirical Evidence of PSCR





Supply chain visibility cannot be
achieved in a highly regulated
environment
Mehralian et al., (2015) Visibility Emerging demand and PSC complexities
inhibits transparency.
Aigbosun et al., (2015) Vulnerabilities and
resilience
Vulnerabilities include turbulence,
sensitivity and external pressures.
Resilience strategies include




Agility capacity Resilience strategies are predominantly
applied at mature stages of the PSC.





using SCRAM tool by
Pettit et al., (2010)
Resilience strategies include visibility,
collaboration, and flexibility.
Tucker et al., (2019) Vulnerabilities and
Resilience
Vulnerability drivers include deliberate
managerial decisions
Table 4 presents a summary of how CAS can be used to extend our understanding of PSC
resilience. The summary suggests that CAS theory can be used as a lens in explaining the
dynamic, adaptive and emergent features of PSC resilience. CAS theory also highlights that
the interactions between agents are non-linear. So the outcomes of the decision-making
process may be uncertain. The above discussion clearly makes the case for the importance of
advancing our understanding of PSC resilience in the face of dynamic disruptions through the
adoption of CAS theory .
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Table 4 A summary of pharmaceutical supply chain resilience as a CAS
3. Research Methods
The goal of this paper was to advance our understanding of PSC resilience using the CAS
Theory. This is in response to the demand for more empirical studies into SC resilience and
specifically to understand resilience in the context of the PSC due to its unique characteristics.
In this paper, we sought to understand why the PSC was susceptible to the impact of
disruptions and how resilience strategies were adopted to reduce the impact of disruption. To
achieve the research objectives, gaining insights into the experiences of actors at various
levels of the PSC was required and justifies the need for a qualitative exploratory study
(Creswell and Poth 2016).
3.1 Data Collection
Respondents in charge of making decisions at various levels of the UK's PSC were selected,
to provide rich, diverse and holistic views of disruptions, vulnerabilities and resilience
strategies. A purposive sampling technique was used to ensure that the research participants
met the criteria specifications set out in the study (Saunders, 2012). Thus the study included
participants representing each level in the PSC: manufacturers, wholesalers, logistic service
providers, secondary and primary care pharmacists. In each case, their job roles involved:
responsibility for decision making with regards to the strategies related to disruption
management in the PSC. Participants were therefore able to provide rich, diverse and
holistic insight into the phenomenon of disruptions, vulnerabilities and resilience strategies.
It was envisaged that 16-24 interviews would be required to achieve data saturation (Hennink
et al. 2017). Participants were recruited until no new information was generated from the
Features CAS CAS and PSC Resilience
Internal
Mechanisms
Concerned with interactions of SC actors with each other when disruptions
occur. Their decision-making process in response to the changes within their
environment. These decisions could include, information sharing,
outsourcing, power dynamics, strategic alliance.
External
Mechanisms
Refers to disruptions which can be dynamic or static such as medicine
shortages, pandemics, natural disasters
Coevolution The outcome of the decision-making process by supply chain actors in
response to environmental changes may either increase resilience or
vulnerability.
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respondents (Morse, 1995). Ultimately this was achieved with data collected from 23 key
pharmaceutical supply chain actors using semi-structured interviews between June 2018 and
August 2018. Telephone interviews and conversations were recorded using a digital voice
recorder, based on the study’s research objective.
Table 5 presents the characteristics of the research participants and how they were coded
before the data analyses.
Table 5 Characteristic of Interview Participants
3.2 Interview Protocol
An interview protocol was developed to ensure that the process of generating the data was
structurally sound. The interview protocol asked respondents why the PSC in the UK is prone
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to the impact of disruptions and how resilience strategies can be employed to mitigate the
impact of these disruptions. The structure of the interview protocol was developed using
critical themes from the SC resilience literature. These themes included: vulnerabilities,
disruption and resilience strategies. Questions around this thematic structure facilitated a
positive interaction with participants and encouraged them to speak more openly about their
perceptions and experiences (Kvale, 1999). The interviews focused on two main categories of
questions; the description of how firms within the PSC handled disruptions when they
occurred. Secondly, the questions explored reasons why these firms felt the impact of SC
disruptions if at all and possible solutions to resolve the impact. The interview protocol
consisted of 20 questions (see Appendix A for interview protocol) with an average duration
of 30 minutes. This protocol enabled the interview process to be replicated across the various
supply chain partners, thus ensuring reliability (Yin, 2013).
In accordance with recommendations by Pettigrew (1997), the interview protocol was piloted
on the first four participants: a manufacturer, a hospital pharmacist, a regulatory body
representative and a community pharmacist. The responses from the pilot study generated
amendments which facilitated the development of the final interview protocol used in the
study. The amendments were minor and related to terminology such as 'disruptions' instead
of 'dynamic disruptions'. These amendments minimised any risk of misunderstanding.
3.3 Data Analysis
All interviews and conversations were audio-recorded with the permission of the respondents.
The interviews were transcribed verbatim and the transcripts anonymised. Interviews were
analysed using thematic analysis which aimed to present a comprehensive account of themes
related to the objectives of the study, rather than a representation of the entire dataset (Braun
and Clarke, 2014). For this study, a 'theme' constituted a pattern of meaning which was either
directly observable in the data (explicit content) or was seen to underlie the data (manifest
content; Joffe, 2012). The use of thematic analysis was chosen because of its flexibility which
is not rooted in any theoretical perspective (Brannen, 2017). As prior research across this
participant group is limited, this approach allowed for analysis to be primarily inductive,
reflecting the experiences of participants.
This study thus followed Braun and Clarke's six-step method for theme development (Braun
and Clarke, 2014). The first step was familiarisation of the data which was achieved through
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repeated readings of the transcripts to understand the data and identify fragments of the data
that referred to various parts of the research questions. The next step was coding where the
interviews were initially coded, and the themes developed by the lead researcher. These
themes were subsequently reviewed by three other experienced researchers in Supply Chain
Management and Pharmacy and any areas of disagreement resolved through discussions. For
further confirmation, an interdisciplinary research group (Operations Management and
Pharmacy) reviewed the output and validated the constructed themes. The use of multiple
researchers in the development of themes, thus reduced any issues of bias that may arise from
a single (Strauss and Corbin, 1990). Although there are software packages developed for
thematic analysis, they did not fit the purpose of this study as it had been developed under
various epistemologies (Petty et al., 2012). Therefore, to maintain control of the data, the
thematic analysis of the data was carried out manually. These themes are presented and
analysed in the following section of this paper.
4. Findings
The interview protocol focused on understanding PSC resilience by exploring vulnerability
drivers and antecedents of resilience strategies as informed by pertinent literature. The data
analysis identified power, conflicts and complexity as a vulnerability driver. At the same time,
recovery and resistance strategies were dimensions of resilience in the PSC. The
characteristics of the supply chain were identified as pertinent in the decision-making process.
A summary of the strength of participants’ agreement with statements linked to the identified
themes is presented below. As indicated in Figure 2, no 1–7 in the diagram denotes drivers of
SCV and 8-11 are the antecedents of SC resilience. The brackets in the diagram highlight the
differences in the categories.
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Figure 2. A summary of the themes and subthemes
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The findings will be presented based on the themes that were evident in the data.
Table 6 Key Summary of Empirical Evidence
Themes Sub-Themes Activities Sample Quotes from the Evidence





“If the pharmacists are selling a product to a competitor in Germany, the pharmacists take the
profit and not the manufacturer…... All I will suggest the pharmaceutical society and the






“If we have low stock, the first strategy is to investigate if we don’t think we can react in time to
bring in additional stock, we would need to put in allocation for the stock to ensure that all of





“Some manufacturers don’t necessarily want the market to know that they are going to go short
in supply …it’s a reputational thing as well”.
Behavioural
Uncertainty
“As a manager of someone in a managerial capacity, you can create drug shortages by panic
buying. If you hear that there is a shortage is likely to occur, the first instance some people will
do is the need to get plenty of that product when it is still available, then demand goes up …One





“A drug used to be on the market selling for maybe £3 to £4, I can’t remember exactly. Amacol
bought the license for this drug, removed it from the market for about six months and sort of
created havoc rereleased it back onto the market with an inflated price of about £20. And that’s






“There is a debate as to understanding the role of pharmacy, additional service to patients or
make profit… certainly the more money you take from the pharmacy…. community pharmacy is
not about making money whereas for the multiples it’s about profit not about service”.
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“Because all these are individual businesses, and all reacting to their own individual strings
and pressures and needs at that time.”
Trust “For instance, the direct to the patient model where the manufacturer supplies directly to the




“Drug shortages occur because somebody else in the chain is making a profit by locking these










“The drugs we predominantly sell are not the type of drugs like other products. It must be like
diabetes, heart failure …… We manufacture based on patient prescription numbers which are
not quite straight forward. I would say the manufacturing of pharmaceuticals is quite a long





Brexit ‘‘Let say BREXIT… because the wholesalers play a major part in the supply chain. If at the
moment they are importing products from other countries and we are not aware of that, if we
are not able to do that pre-Brexit then we will find that demand for products in the UK will
increase and we might not have forecasted the market”.
Parallel trade Other problems will be related to parallel trade, using an example where there is a product
which is an eye care product and 10% of the sales of the product are the UK taxed which we
distribute, 90% are products that are imported into the UK. The parallel importers for whatever
reason had problems with getting hold of the products and so suddenly we were faced with an
increase in demand of 10 times what the normal demand was. On an average, we would have
1.5 to 2 months of stock so very quickly we ran out of stock for that product and there was a gap
between 6 to 8 weeks before we were in a position to supply”.
Mergers and
Acquisition
“In the last few years, a lot of big manufactures have merged together so there is less variance,




“For instance, a lot of drug shortages around Europe have been caused by the constant change
in regulatory bodies. The FDA going to manufacturers saying the standards have changed. For
manufacturers to meet up with these requirements, they must disrupt their manufacturing
process”
Price “The trouble is, for instance, if this is June; they don’t normally accrue till the end of June. So,
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reimbursement you have dispensed all though June those prescriptions let’s say Lamotrine. Sometimes you must
go all through your prescriptions, take them out and send them in July so you get the higher






“So what happened with that was that you may have decided 100mg may have gone out of stock
originally so you double up with 50mg and everyone was doing that it took a good three or four
weeks for things to settle down because people were trying to make do with whatever “.
Alternative
form
“A coping strategy might be to use syrup instead of a tablet, or strength of tablet rather than the
strength that is out of stock or a non-sustained release rather than a sustain release. For




“I occasionally have to buy from the main short-line if I get something; I pay over tariffs to




Obviously, we had to communicate to the customer to tell them what the situation was especially
if the disruption was going to last longer”.
Joint Decision
Making
Joint planning “We would have a local meeting to discuss the situation, a local meeting within the stakeholders
across our business, so our regulatory colleagues, our quality colleagues supply chain and also
our communication with colleagues as well”.
Resistance
Strategies
Resource sharing Technology “It’s not effective for each trust to be doing the same thing. NHS trust is spending time. It should
be done centrally. Some sort of central resource like they have in the US is a good example.
Foster information sharing. It’s about developing a centralized resource to help manage the




“Because of our alliance with bigger firms, our buying is better. The company we buy from tend
to build bulk order in advance; a lot of smaller independents really struggle for stock we recover
more quickly because we tend to hold on to stock longer than other people would have.”




4.1.1 Supply Chain Power
According to our findings, power dynamics increased vulnerability in the PSC. Three
instances that depicted the presence of power were: control of drug flow; control of
information, and price control. A summary of power as an SCV is presented in Figure 3.
The findings indicated that SC actors, controlled drug flow using the quota system, to protect
their revenue stream and to ensure patients' treatment continuity. The quota system involved
rationing of drug allocation or withholding products from SC actors until scanned copies of
patients' prescriptions were received. Since some SC actors were perceived to be selling their
excess drugs abroad for profit, manufacturers of the product faced revenue losses and
imposed the quotas. Also, to ensure there were sufficient supplies for patients to remain on
medications throughout the disruptions, restrictions on product distribution was imposed.
Information control within the PSC was to protect the reputation of SC actors and avoid
behavioural uncertainty such as panic buying. Thus, some SC actors were hesitant to divulge
information about disruption because they feared news about their situation might affect
reputation and market share. Besides, supply chain actors indicated that they were uncertain
about the reaction of their supply chain partners when they received information about a
disruption.
The data also revealed that some SC actors were perceived to control prices in the PSC. The
control of prices began by creating artificial demand for some products and then
reintroducing these products into the market for profit. These scenarios were prevalent in
instances when the SC partner had not reached their sales target. As such, product prices
could be manipulated by SC partners who had the power over the prices and products within
the SC.
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Figure 3. Power as a vulnerability in the PSC
4.1.2 Supply chain conflict
Our findings indicated that the absence of trust, misalignment of organisational goals and the
asymmetric relationship within a SC created conflict. The inability of SC actors to audit the
behaviours of their partners and/or in some instances, evaluate the quality of resources
brought to the SC affects the level of trust. The absence of trust thus reduces SC partners’
satisfaction and creates conflict within the PSC.
Misalignment of the goals of SC partners also increased the incidences of conflict. For
instance, using tenders, the NHS's objective was to supply drugs to patients at the minimum
possible price. Manufacturers producing branded products who could not compete favourably
for lower prices with the tender system sought alternative markets or in extreme cases ceased
production. Thus the tender system can drive suppliers out of the market, and this increases
SCV.
Another indicator of SC conflict was the presence of asymmetric relationships amongst SC
partners, and this affected the level of partners' satisfaction among SC actors. Asymmetric
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relationships emanated from the amount of control the manufacturer and the regulatory
bodies had over material and information in the SC. These dominant activities bred
asymmetric relationships that led to conflict and partner dissatisfaction and increased SCV.
4.1.3 Supply Chain Complexity
Complexity within PSC were also deemed pertinent as a vulnerability driver in this study.
Antecedents of PSC complexity included product/process characteristics, regulations,
economic and political issues.
Our findings showed that the product and production process characteristics were SCV
drivers. These SCV drivers included production lead times, product composition, scarcity of
alternatives, storage and distribution process as well as the product life cycle. The responses
from the interviews identified that for pharmaceutical products to be effective, they had to be
the right product, taken in the right dosage, strength and at the right time. For production
lead times, the findings indicated that pharmaceutical products differed significantly from
other products as manufacturing usually took about eight to twelve weeks. Product and
production processes of pharmaceutical products were usually subject to the specificity of the
product, manufacturing complexity and stringent regulations. These complexity made it
difficult for SC actors to respond timely during a disruption and a such exposed the SC to the
impact.
Economic and political issues were also identified as elements of complexity within the PSC.
Uncertainties related to these led to issues such as stockpiling. Mergers and acquisitions
were also an economic issue that added complexity to PSC. The respondents indicated that
the processes of big pharmaceutical companies who had products coming off patent merging
with smaller pharmaceutical firms usually created monopolistic behaviours which were
detrimental to the PSC. Another example of economic uncertainty was the issue of parallel
trade. The findings showed that although trading of pharmaceutical products within the
European Union was legal, SC actors took advantage of the weakening British pound against
the Euro to make profits. The whole movement of pharmaceutical products across borders
confused demand signals and caused chaos when inadequately managed.
4.2 Resilience Strategies
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Two forms of resilience strategies emerged from the data and were classified as either 1)
recovery or 2) resistance strategies. For recovery strategies, the data revealed that several
measures that PSC actors employed in mitigating the impact of disruptions were strategies
that facilitated the 'return to normal operations' of the SC; hence the term 'recovery'. These
recovery strategies included flexibility, visibility and joint decision making. Regarding
flexibility, the data indicated that two forms of flexibility were used in recovering from a
dynamic disruption. These were flexibility relating to the form and or/volume of medicines
flexibility and supplier /logistic flexibility. For form/volume flexibility, the respondents
explained that to recover from a disruptive activity, using products that had similar strengths,
or a suitable clinical alternative at the right dosage or available combinations of products
were the viable options for patients' treatment continuity. Flexibility was particularly relevant
depending on the product the disruption had affected. Supplier logistics entailed seeking a
new supplier.
Visibility through information sharing within the SC was identified as an effective strategy
used in recovering from a disruption in this study. Information sharing here was concerned
with the flow of stock and demand levels. For example, primary care respondents said they
were able to closely monitor product flow from their suppliers through an online database,
and when the stock level was on red, it was an indication that there was a problem with
products which required further inventory planning.
The findings from the interviews also suggests that in the event of disruptive activity, joint
decision making had a positive impact. Jointly planning strategies with SC partners helped all
SC actors to restrict the negative impact on patients' treatment continuity as well as
maintaining operations. On the matter of maintaining operations, one of the manufacturers
proved that joint planning was valuable as all stakeholders jointly developed strategies on
how to tackle the impending disruption. It involved meetings to inform SC actors about the
disruption and its duration. They jointly decided the best possible course of action, and this
was carried out to prevent operational as well as financial losses and potentially the death of
patients. The decision-making involved the stakeholders attending to various aspects of the
SC.
The regulatory bodies acted as intermediaries between competitors to see if production could
be ramped up to meet demand, as it was against competition laws for manufacturers to
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discuss this directly with other manufacturers. The Commercial Medicines Unit (CMU) and
the Department of Health and Social Care (DHSC) had conversations with secondary care
pharmacists to determine how to recover from the disruption. These recovery strategies were
either through sourcing alternatives products, rationing, importing from abroad or
manufacturing within the NHS production plant.
For resistance strategies, the data analysis showed that through the sharing of resources with
SC partners, the PSC was able to plan and prepare for disruptions. This sharing of resources
was only feasible when strategic alliances had been formed which enabled actors share timely
information, infrastructure and technology. As such, SC actors were able to pre-plan for
disruption and curtail its impact. A community pharmacist that engaged in strategic alliance
practices explained that their suppliers usually provided up to date information about pending
disruptions as well as provision of the infrastructure to stockpile. This strategy is in contrast
with the 'just in time' practices that are in existence with independent SC actors.
Our findings highlight that it was challenging to explain SCV and resilience strategies
separately as some of the decisions that depicted vulnerabilities were actually strategies used
to achieve market share by some of the SC actors. For instance, the manufacturers reported
that they controlled the flow of medicines in the SC to ensure the flow of their revenue
stream. This action was perceived as a vulnerability by other SC actors as it hampered
adequate planning and further compounded the impact of disruptions. The findings also
revealed that some SC actors adopted decisions based on the characteristics of the entire PSC.
For instance, some pharmacists chose not to stock some product because of the pricing
regulation involved in reimbursement. Pricing reimbursement is standard practice in this PSC.
The underlying argument here is that, although the findings attempted to categorise
vulnerabilities and resilience strategies separately, there was evidence to confirm the
relationship between vulnerabilities and antecedents of SC resilience. These relationships
may sometimes lead to outcomes such as flexibility and/or power asymmetry as a result of
misalignment of goals. These relationships depict non-linearity as a fundamental element of a
CAS. The next section, therefore, discusses the findings using CAS as a framework for
explaining PSC resilience.
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5. Discussions on Building Pharmaceutical Supply Chain Resilience
Our findings have provided evidence to suggest that advancing our understanding of PSC
resilience can be explained effectively by adopting the CAS lens and its key components:
internal, external and co-evolution. This implies that vulnerabilities and resilience strategies
are all interconnected in the building of resilience in the PSC.
5.1 Supply Chain Vulnerabilities
The findings established that the presence of power, conflicts and complexity increased the
PSC susceptibility to the impact of medicine shortages as a dynamic disruption. With regards
to power, the ability of SC actors to control the basic tenets of the SC product, information
and price depicts the presence of power asymmetry (Benton and Maloni, 2005, Bandara et al.,
2017). The findings revealed that SC actors, controlled the flow of drugs using a quota
system, controlled information and prices. The control of drug flow through the PSC,
however, hampered SC actors' ability to plan for disruption, thus increasing the susceptibility
of the PSC (Tukamuhabwa et al., 2015; Hendry et al., 2019). Although the presence of
power asymmetry was to ensure the efficiency of operations and financial performance of
their firms, it ultimately increased SCV.
From the findings we see that the divergent organisational goals of SC actors increased the
incidences of conflicts, and this increased the vulnerability of this service SC. A careful
examination of the data revealed that not all actors in the PSC engaged in business activities
to make a profit, and these differences created conflict. Factors signalling misalignment of
goals in the study included: NHS strategy through the tender system, service orientation of
the pharmacists and profit margin goals for manufacturers. These activities may lead to
decreased efficiency and diminished services in the SC. Also, the differences in
organisational goals created conflict and made it difficult for SC actors to collaborate in order
to strengthen the PSC as asserted by Lundin and Norman (2010).
The absence of trust reduced SC partners’ satisfaction and as such increased the potential for
conflict within the PSC according to the findings. The presence of trust is pivotal for sharing
information between SC partners (Barratt and Oke, 2007). However, as a result of the
absence of trust, which was evidently absent among actors in the PSC, information sharing
was limited; this increased SCV SC actors were unable plan and or respond promptly.
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Complexity was also identified as a driver of vulnerability in the PSC and aligns with other
researchers that have highlighted complexity as an impediment to the operational and
financial performance of SCs (Craighead et al., 2007). There were also interrelationships
between the vulnerability drivers. For instance, although the display of power emerged as a
result of revenue flow, behavioural uncertainty and reputation. Another underlying issue was
as a result of the absence of trust, which inadvertently increased SC conflict. Also, the display
of power may further increase uncertainties like those related to economic and/or political
issues.
5.2 Supply Chain Resilience
Recovery and resistance strategies were the primary mechanisms that enhanced resilience in
the PSC according to the findings in this study which aligns with existing literature (e.g.
Blackhurst et al., 2011; Scholten et al., 2019). Flexibility, visibility and joint decision-
making were the antecedents for recovery strategy while strategic alliance was employed as a
resistance strategy.
According to our findings, in the PSC, flexible operations consisted of the ability of SC
actors to employ alternative forms of treatment in the right dosage, volume or form to ensure
the continuity of patient treatment. However, this strategy was used after a disruption had
occurred by patient-facing SC actors to enable them to respond quickly to patients' demands.
Thus, flexibility in the PSC may be a temporary departure from practice as a short-term
solution and may not be sustainable as argued by Fayezi et al., (2017).
SC visibility is referred to as the ability to access viable (timely, accurate and purposeful)
information, which provides a reliable description of supply and demand (Wei and Wang,
2010). Our findings indicated that the timing and quality of information shared were pertinent
for building recovery mechanisms in the PSC. Information quality was measured by the
ability of SC actors to state the cause and length of the disruption as well as other useful
information, such as the availability of alternatives (Brandon-Jones et al., 2014) and
(Scholten and Schilder, 2015). The reaction of stakeholders to information shared on
impending SC disruptions, however, restricted the type of information SC actors shared,
which reduced visibility and increased SCV (Juttner and Maklan, 2011). For instance, the
findings showed that sharing information about a disruption triggered panic buying which led
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to further disruptions. This argument thus provides possible explanations for the reluctance of
SC partners to share information regarding disruptive activities.
Our findings indicated that joint decision making as a recovery mechanism contributed to
building resilience in the PSC. The success of the joint decision-making process in this study,
stemmed from relationships that had been built among SC partners over the years, as asserted
by Li et al., (2015). Thus, to successfully agree on mutually defined goals, reduce operating
costs and encourage better use of external resources, relationships had to be developed. The
joint decision-making strategy adopted by actors in the PSC is, however, a recovery
mechanism which differs from existing literature where coordination of decisions is a
proactive, collaborative process (Scholten et al., 2019).
The findings showed that resistance strategies provided SC actors with the capacity to
prepare for disruption. Resistance strategies were developed by forming strategic alliances
and this involved sharing of infrastructure and stockpiling (holding buffer stock with SC
partners). Strategic alliance in the PSC was successful among SC partners who had closely
linked goals, and it involved independent tasks from each SC actor. In this arrangement,
manufacturers formed strategic alliances with wholesalers as well as community pharmacists
in the SC, where the wholesalers engaged in the warehousing and transportation of the
manufacturer's products and the pharmacists aided in the distribution of manufacturers'
products at the community level. Strategic alliance here increased visibility, information
sharing and facilitated decision-making. SC actors were, therefore, able to mitigate the
impact of disruption by forming strategic alliances, as explained by (Minerbo et al., 2018).
Thus, strategic alliances were critical in building resilience strategies in service SCs such as
PSC.
5.3 Understanding PSCR as a CAS
Using CAS theory, we describe how the interactions between SC actors, build SC resilience
at a systemic level.
First, our findings indicated that the PSC is an open system that interacts with its environment
and these interactions influence the ability of the PSC to develop resilience strategies (Nair
and Reed- Tsochas, 2019). For instance, in the event of a disruption, the manufacturer
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responds to this disruption by sharing timely information with other SC actors. The sharing of
information provides SC actors with the ability to plan and prepare for the disruption and as
such, makes the PSC more resilient to the impact of disruption (Tukamuhabwa et al. 2015).
However, controlling of information about disruption increases the susceptibility of the PSC
vulnerable. Also, in responding to parallel trade in the environment, some wholesalers and
pharmacists decide to sell abroad for profit, especially when the exchange rate is favourable.
Manufacturers impose quota systems to reduce parallel trading and to control their revenue
flow. Thus, the decision-making process by SC actors in responding to the environment
builds resilience strategies or drives SCV.
Our results also reflected that SC actors act independently and are primarily guided by
internalised goals (Nair and Reed-Tsochas, 2019). Participants in our study indicated that
they had diverse goals. The goal of the NHS was to provide quality medicines at the lowest
possible cost. The community pharmacists indicated that their goal was service-oriented;
seeking patient safety, and the manufacturers identified making a profit as their internalised
goal. These internalised goals provided SC actors with reference points for their behaviour.
For instance, since the goal of the manufacturer was to make a profit, their inability to
compete favourably for tenders by the NHS forced them to seek profits in other markets and
thus increased vulnerabilities in the PSC. When their goals were strategically aligned, as seen
in the case of a strategic alliance among SC actors, they developed resilience to disruptions.
Since internal goals guide SC actors, their interactions produce non-linear dynamics as in a
CAS system (Choi et al., 2001; Holland, 2006). In this study, an example of non-linear
interactions is conflict. For instance, pharmacists explained that they wanted to ensure
patients continued their treatment and as such stockpiled products. Manufacturers also
introduced quotas to control their revenue stream. The outcome of these interactions
produced elements of conflicts such as the absence of trust and asymmetric relationships and
made the PSC vulnerable to the impact of disruptions.
Interactions between SC actors also produced new behaviours. These learned behaviours
emanated from past interactions between SC actors. Our findings showed that as a result of
manufacturers sharing information about a disruption, this led to stockpiling, thus creating
false demand and manufacturers decided to display their power. Also, SC actors' decision to
jointly share resources to increase visibility and flexibility depicts strategic alliances are
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formed as a new behaviour. SC actors, thus, learned from these past actions to make new
decisions when disruptions occured, which caused the SC to evolve.
Figure 4 portrays PSC resilience as a CAS, which includes the internal environment and the
external environment. The underlying processes involved in developing resilience in the PSC
stem from SC actors' interactions with each other given underlying PSC characteristics in
responding to their external environment. The outcome of these interactions either build
resilience into the PSC or increase SCV.
Figure 4. Supply chain actors’ decision-making process.
6. Conclusions
This study aimed to advance our knowledge of PSC resilience using CAS theory. In order to
achieve the research objective, the study explored why the PSC was susceptible to the impact
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of disruptions and considered how resilience strategies had been employed to reduce the
impact of disruptions in the PSC using CAS theory as a medium for further exploration.
Our study found that the presence of power, conflict and complexity within the PSC
increased SCV. Resilience strategies were developed by increasing flexibility, visibility,
joint decision making and strategic alliances in the SC. The findings also demonstrated that
understanding and developing resilience in this service SC involved adopting a systemic
approach that included disruptions, vulnerabilities and resilience strategies. This is in line
with CAS theory which advocates a holistic approach to understanding a system rather than
parts of the whole (Day, 2014; Nair and Reed-Tsochas, 2019). Through the CAS lens,
therefore, it can be seen that the outcomes of these resilience strategies stem from the vertical
interactions of SC actors in response to their environment. Thus, resilience in the PSC as a
complex system is based on its existing internal mechanisms and its reaction to external
mechanisms.
6.1 Research Contributions
In this study, we argue that recognising PSCR as a complex system is an essential step in
designing the PSC that can advance the services of this SC. Proponents of CAS theory (Choi,
2001; Day, 2014; Tukamuhabwa et al., 2015) hitherto have not emphasised the importance of
vertical collaboration and the decision-making processes of SC actors whilst simultaneously
adapting to changes in the external environment. This study, therefore, extends the CAS
theory by providing explanations as to how SC actors interact to develop resilience to the
impact of disruptions. The findings also extend existing SCV literature by identifying the
presence of power as a vulnerability driver which has not been previously recognised.
6.2 Areas for Further Research
The limitations identified in this study could be targeted as avenues for further research.
First, the exploratory nature of the study inhibited examining underlying vulnerabilities and
resilience strategies from various vantage points. Examining PSCR for specific medicines
within the PSC like orphan drugs to see if their SC differs woul be advantageous. Secondly,
prioritisation tools such as the Multiple Criteria Decision Making (MSDM) could be used to
develop vulnerability tools in assessing suppliers' tendering capacity and the selection of
partners for strategic alliances. Thirdly, whilst this study did advance the understanding of the
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PSC as a service SC utilising CAS theory, it did not measure the starting and endpoints for
PSCR strategies. As such, future studies in this area should examine at what point SC actors
develop resistance strategies in time to combat disruptions within the SC. Finally this study
focused on the UK PSC, which comprised of manufacturers, wholesalers, primary care,
secondary care, and regulatory bodies. Future studies should include other SC actors like;
packaging, labelling, and parallel trading firms to provide a broader insight into PSC
resilience and similar studies in other parts of the world would provide a useful comparison
6.2 Recommendations
The findings from this study can aid SC actors in the planning and preparation for SC
disruptions. It validates the pursuit of understanding the interactions and decision-making
processes of key SC actors as a critical driver of resilience in the PSC. The finding can also
provide managers with insights into investment decisions regarding the best resilience tools
to use. For instance, manufacturers can invest in visibility tools to facilitate the sharing of
information and increase traceability of products which will significantly reduce the impact
of disruptions and further advance the services of the PSC
This study has focused on medicines unavailability, which is a fundamental issue in the PSC.
The current COVID 19 has again raised awareness of the importance of this SC and its
products. The history of medicines shortages highlights its fragility. It is for all these reasons
that exploring complexity in this service SC is critical. Learnings from this study (approach,
methodology and outcomes) apply to professionals in other complex service SCs such as
humanitarian logistics, blood SCs, perishable food SCs and patients in healthcare SCs.
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